My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: COG AALL0434

Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma


This study will determine whether the addition of an experimental drug, called Nelarabine, will improve the chance of getting rid of T-NHL for as long as possible with acceptable side effects, when compared to the augmented therapy without Nelarabine. Participants in this study have been diagnosed with T-cell Lymphoblastic Lymphoma (also called T-NHL). T-NHL is a cancer of the lymph system, which is made up of the lymph nodes and other lymph tissue throughout the body. Lymph tissue makes and stores infection fighting white blood cells called lymphocytes. These cells become cancerous when a patient has T-NHL. The overall goal of this study is to see if we can improve the chances of getting rid of the cancer for as long as possible with acceptable side effects of therapy. We also want to study the lymphoma cells to better understand how to improve the treatment of this disease.

Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner MD,Samuel Anim, MD
ALL (Acute Lymphocytic Leukemia), NHL (Non-Hodgkins Lymphoma)
Phase III


Active - Partially Closed to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list